The strong selective pressure against TP53 correction likely reflects the central role of p53 in maintaining genomic integrity and suppressing tumorigenesis, whereas the more moderate effects observed for SMAD4, PTEN, and KRAS may be due to redundancy in signaling pathways or compensatory mechanisms within the cancer cells. This evidence concerns the gene TP53 and cancer.